The HSP90 Inhibitor, AT13387, Displays Single Agent Activity in Erlotinib-Sensitive and -Resistant Models of EGFR-Activated NSCLC Keisha Hearn, Tomoko Smyth, Jon Lewis, Vanessa Martins, Neil Thompson, Mohammad Azab, John - Hearn - Document - PDFSEARCH.IO

First Page	Meta Content
	The HSP90 Inhibitor, AT13387, Displays Single Agent Activity in Erlotinib-Sensitive and -Resistant Models of EGFR-Activated NSCLC Keisha Hearn, Tomoko Smyth, Jon Lewis, Vanessa Martins, Neil Thompson, Mohammad Azab, John Add to Reading List Open Document File Size: 482,49 KB Share Result on Facebook City Cambridge / NCI / / Company HSP90 / Astex Pharmaceuticals Inc. / Nicola G. Wallis Astex Pharmaceuticals / Wallis Astex Pharmaceuticals / / Event FDA Phase / / MedicalCondition resistant disease / Cancer / xenograft tumors / tumors / non-small cell lung cancer / NSCLC / EGFR-activated tumor / / Person Keisha Hearn / Jon Lewis / Mohammad Azab / Vanessa Martins / Neil Thompson / Tomoko Smyth / John Lyons / / Product H1975 / AT13387 / / Technology Genotype / / URL www.astx.com / / SocialTag Amines Organofluorides Alkynes Organochlorides Gefitinib Erlotinib Epidermal growth factor receptor Hsp90 Protein kinase inhibitor Chemistry

The HSP90 Inhibitor, AT13387, Displays Single Agent Activity in Erlotinib-Sensitive and -Resistant Models of EGFR-Activated NSCLC Keisha Hearn, Tomoko Smyth, Jon Lewis, Vanessa Martins, Neil Thompson, Mohammad Azab, JohnAdd to Reading List